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RA DI Ol M MU NO LOGI CA L BEHAVIOUR OF 
ENDOGENOUS AND EXOGENOUS 
HUMAN GROWTH HORMONE* 
K. von WERDER, C . DESALM, S. GALLENBERGER, 
M . GOTTSMANN, P .C. SCRIBA 
II. Medizinische Klinik der Universität München, 
Munich, Federal Republic of Germany 
Abstract 
RADIOIMMUNOLOGICAL BEHAVIOUR OF ENDOGENOUS AND EXOGENOUS HUMAN GROWTH HORMONE. 
The immunoreactivity of endogenous human growth hormone (HGH) and of exogenous HGH after 
infusion into patients has been investigated. Four different HGH preparations gave identical Standard curves 
documenting immunoidentity. Complete immunoidentity could not be demonstrated for "big" HGH which 
was separated from regulär HGH by dextran gel filtration. The HGH immunoreactivity. which was eluted 
from the column ahead of "big" HGH, showed an even more pronounced change in immunoreactivity. 
Exogenous and endogenous human placental lactogen (HPL) showed the expected deviation from the HGH 
Standard curve, whereas bovine prolactin (BPr) and high endogenous immunoassayable HPr (3200 ng/ml) did 
not cross-react with the HGH antibody. Immunoidentity of HGH with the Standards was documented in 
10 patients with acromegaly. This was true for samples from the jugular vein as well as from the periphery. 
Eight insulin tolerance tests (ITT) were performed in patients with normal HGH secretion. Samples at 30, 45, 
60 and 90 min were diluted and the resulting slopes compared with the Standard curve. Whereas the slopes 
of the 30-, 45- and 60-min samples were parallel, the slopes of the 90-min samples deviated from the 
Standard curve. Exogenous HGH was infiised (2 mg for 30 min for each person) into five normal subjects (I) and 
five patients with HGH deficiency (II). HGH levels rose to 171. 6 ± 19. 8 ng/ml (I) and 192.4 ± 34. 8 ng/ml (II). 
HGH half-time of disappearance was 14.9 ± 3.9 min (I) and 19.1 ±6 min (II). There was no change of HGH 
immunoreactivity over a period of 2 hours. 
In summary: (1) Cross-reactivity of HPL but not of HPr with HGH antibodies was demonstrated. 
(2) HGH in acromegaly and exogenous HGH after infusion have identical immunoreactivity. (3) The change 
in endogenous HGH immunoreactivity 90 min after Stimulation is apparently due to the secretion of a 
different HGH immunoreactivity that is most likely residing in a larger molecular weight fraction. 
R a d i o i m m u n o a s s a y has become the method of choice for m e a s u r i n g 
peptide h o r m o n e s and other substances in b i o l o g i c a l f l u i d s s ince the 
development of the f i r s t r a d i o i m m u n o l o g i c a l d e t e r m i n a t i o n for i n s u l i n by 
Y a l o w and B e r s o n [ 1 ] . One of the c r i t e r i a f o r the v a l i d i t y of r a d i o i m m u n o -
a s s a y s i s the ident i ty of the i m m u n o r e a c t i v i t y of the Standard p r e p a r a t i o n 
and the unknown substance w h i c h i s m e a s u r e d i n the body f l u i d [2 , 3 ] . In 
the case of i m m u n o i d e n t i t y , the Standard curve and the d i l u t i o n c u r v e of the 
unknown w i l l r u n p a r a l l e l . A dev ia t ion of the d i l u t i o n curve f r o m the 
Standard c u r v e is e i ther due to a di f ferent antigen w i t h s i m i l a r , but not 
i d e n t i c a l , i m m u n o r e a c t i v i t y o r to c a t a b o l i c p r o c e s s e s in the body f l u i d 
changing the i m m u n o d e t e r m i n a n t s i te of the o r i g i n a l ant igen . 
H u m a n g r o w t h h o r m o n e i s a Single-chain peptide w i t h a m o l e c u l a r weight 
of 21 500 [ 4 ] . It has been shown by s e v e r a l i n v e s t i g a t o r s that H G H -
i m m u n o r e a c t i v i t y i s a l s o found i n a l a r g e r m o l e c u l a r weight f r a c t i o n i f 
p i t u i t a r y - o r s e r u m - H G H i s subjected to dext ran g e l f i l t r a t i o n [5 , 6, 7 ] . 
The ex i s tence of " b i g " h o r m o n e s , as have been d e m o n s t r a t e d for i n s u l i n [ 8 ] , 
p a r a t h y r o i d hormone [ 9 ] , g a s t r i n [ 1 0 ] , A C T H [11] and HGH [5 , 6, 7 ] , i s 
* Supported by DFG/SFB 51. 
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not f u l l y e x p l a i n e d . T h e y can r e p r e s e n t p r o h o r m o n e s as has been shown f o r 
i n s u l i n [ 8 ] , h o r m o n e s bound covalent ly to prote ins [11] o r aggregated 
hormone c o m p l e x e s . S ince p r o h o r m o n e s should have a di f ferent t e r t i a r y 
s t r u c t u r e because they contain a d d i t i o n a l amino ac ids a d i f ference in 
i m m u n o r e a c t i v i t y c o m p a r e d wi th the f i n a l hormone could be encountered. 
The amino a c i d sequence and the i m m u n o r e a c t i v i t y of H G H i s different f r o m 
the other p i t u i t a r y h o r m o n e s except that human p r o l a c t i n ( H P r ) seems to 
have a s i m i l a r s t r u c t u r e [ 12] . E v e n m o r e r e l a t e d in b i o l o g i c a l a c t i v i t y , 
amino a c i d sequence and i m m u n o r e a c t i v i t y i s human p l a c e n t a l lactogen 
( H P L ) [ 1 3 ] . T h u s , c r o s s - r e a c t i v i t y of H P L with H G H ant ibodies has been 
found [14, 1 5 ] . 
T h e f o l l o w i n g study was des igned to invest igate the i m m u n o r e a c t i v i t y of 
v a r i o u s p i t u i t a r y H G H preparations before and af ter Separation into " b i g " 
and regulär H G H . T h e i m m u n o r e a c t i v i t y was i n v e s t i g a t e d by c o m p a r i n g the 
s lope of the r e s p e c t i v e d i l u t i o n c u r v e s w i t h the Standard c u r v e of a r e f e r e n c e 
p r e p a r a t i o n . T h i s method was a l so a p p l i e d to study the i m m u n o r e a c t i v i t y 
of endogenous s e r u m H G H . H G H of patients wi th a c r o m e g a l y as w e l l as 
endogenous H G H af ter m a x i m a l Stimulation i n patients w i t h n o r m a l pituitary 
funct ion w e r e i n v e s t i g a t e d . In addi t ion to the endogenous H G H exogenous 
H G H a f te r i n f u s i o n into human subjects was i n v e s t i g a t e d . T o determine 
the degree of c r o s s - r e a c t i v i t y of H P L and H P r wi th o u r H G H antibody, 
d i l u t i o n c u r v e s of endogenous and exogenous H P L and endogenous H P r w e r e 
c o m p a r e d wi th the H G H Standard c u r v e . 
M A T E R I A L S A N D M E T H O D S 
H G H was m e a s u r e d by a semiautomated double antibody r a d i o i m m u n o -
assay [ 1 6 ] . T h r e e d i f fe rent H G H p r e p a r a t i o n s w e r e used: Roos H G H [17] 
conta in ing 2 I U / m g p r o t e i n ( K a b i , Sweden, Lot N o . 19156), W i l h e l m i H G H 
(Societa R i c e r c h e I m p i a n t i N u c l e a r i , S a l u g g i a , Italy) and Raben H G H 
conta in ing 2 I U / m g p r o t e i n . A s r e f e r e n c e p r e p a r a t i o n , h ighly p u r i f i e d 
W i l h e l m i H G H f r o m the N a t i o n a l Institute of H e a l t h (batch N I H - G H - H S / 3 9 4 ) 
was u s e d . H G H Standards as w e l l as the s e r u m samples were di luted w i t h 
0 . 1 3 M b o r a t e buf fer , pH 8 .4 , conta ining 0 .5% bovine a l b u m i n . It could be 
d e m o n s t r a t e d that the r e c o v e r y of exogenous H G H added to H G H - f r e e s e r u m 
was not s i g n i f i c a n t l y i n f l u e n c e d by a d i lu t ion up to 1:200 w i t h the assay 
b u f f e r . The graphs of the d i l u t i o n c u r v e s were made i n the fo l lowing way : 
the B / B 0 r a t i o of the highest s e r u m d i l u t i o n was used to d e t e r m i n e the H G H 
c o n c e n t r a t i o n . The H G H concentra t ion of this s a m p l e was r e a d f r o m the 
steepest and most accurate part of the Standard curve between 0.5 and 1.5 ng 
and was r e g a r d e d as the r e f e r e n c e c o n c e n t r a t i o n . F r o m th is r e f e r e n c e 
concent ra t ion the concentrat ions of the other d i lut ions w e r e ca lcu la ted and 
the ac tua l B / B 0 r a t i o was m a r k e d i n the c o - o r d i n a t e System. The r e s u l t i n g 
d i l u t i o n c u r v e s as w e l l as the Standard c u r v e s w e r e log i t t r a n s f o r m e d 
a c c o r d i n g to R o d b a r d [18] w h i c h made the Standard c u r v e l i n e a r f r o m 1 to 
10 n g / m l . 
I n s u l i n h y p o g l y c a e m i a tes ts w e r e p e r f o r m e d a c c o r d i n g to Greenwood 
et a l . [ 1 9 ] . T h e d iagnos is of act ive a c r o m e g a l y was c o n f i r m e d by glucose 
n o n - s u p p r e s s a b l e e levated H G H l e v e l s [ 2 0 ] . D e x t r a n ge l f i l t r a t i o n was 
p e r f o r m e d on a 3 c m X 110 c m c o l u m n of Sephadex G - 7 5 . The buffer used 
f o r the g e l f i l t r a t i o n and in the r a d i o i m m u n o a s s a y of the eluate was 0. 0 5 M 
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s o d i u m phosphate buffer wi th 0 . 1 % s o d i u m a z i d e , p H 7 . 5 . F o r r a d i o -
i m m u n o a s s a y 0 .5% bovine a l b u m i n was added to th is b u f f e r . The c o l u m n 
was sa tura ted wi th 5 m l of 5% a l b u m i n before c h r o m a t o g r a p h y . 1 2 5 I - H G H 
was l a b e l l e d a c c o r d i n g to Hunter and G r e e n w o o d [ 21] and p r e p u r i f i e d on a 
Sephadex G - 5 0 c o l u m n . The pooled p r o t e i n peak was then e luted on the 
G - 7 5 - c o l u m n and f r a c t i o n s of 10 m l were c o l l e c t e d . The r a d i o a c t i v e m a t e r i a l 
e l u t i n g at K D 0 . 8 (peak III) was used as t r a c e r f o r H G H r a d i o i m m u n o a s s a y . 
F o r t y jug of c l i n i c a l - g r a d e p i t u i t a r y H G H (Roos) and 2 m l of s e r u m f r o m an 
a c r o m e g a l i c patient w e r e used f o r Sephadex c h r o m a t o g r a p h y . F o r the r a d i o -
i m m u n o a s s a y of the c o l u m n eluate two di f ferent H G H ant ibodies — goat 
a n t i - H G H and g u i n e a - p i g a n t i - H G H s e r u m — were u s e d . T h e r e c o v e r y of 
the l a b e l l e d H G H ranged f r o m 90 to 100%, that of the n o n - l a b e l l e d H G H 
f r o m 80 to 90%. 
T h e H G H used f o r i n f u s i o n was the same Roos p r e p a r a t i o n as that used 
for c h r o m a t o g r a p h y ( G e r m a n K a b i , L t d . , M u n i c h ) . 2 m g of t h i s p r e p a r a t i o n 
i n 250 m l of sa l ine w e r e in fused for 30 m i n into f ive subjects w i t h n o r m a l 
H G H s e c r e t i o n and f i v e patients w i t h H G H d e f i c i e n c y . B l o o d s a m p l e s f o r 
r a d i o i m m u n o a s s a y w e r e taken unt i l 3 hours a f ter the s tar t of the i n f u s i o n . 
The b i o l o g i c a l a c t i v i t y of the H G H was v e r i f i e d by m e a s u r i n g the i n c r e a s e 
i n c o n c e n t r a t i o n of f r e e fatty a c i d s i n s e r u m and by i t s effect upon g l u c o s e -
s t i m u l a t e d i n s u l i n s e c r e t i o n [ 22] . 
R E S U L T S 
T h e d i l u t i o n c u r v e s (= Standard curves) of the three H G H p r e p a r a t i o n s 
and the N I H r e f e r e n c e H G H were shown to be i d e n t i c a l w h i c h demonstra tes 
i m m u n o i d e n t i t y of the Standard p r e p a r a t i o n s . The d i l u t i o n c u r v e of the 
T S H p r e p a r a t i o n (NIH, b i o l o g i c a l a c t i v i t y 3 .5 I U / m g prote in) shows an 
i n h i b i t i o n p a r a l l e l to the H G H Standard c u r v e . T h i s i s due to contaminat ion 
of the T S H wi th H G H ( F i g . 1). F r o m the T S H i n h i b i t i o n c u r v e i t can be 
deducted that 100 nU of the T S H contain 1 ng of H G H . T h e r e i s p a r t i a l 
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FIG. 1. HGH Standard curve and inhibition curves of TSH, LH BPr and HPL with the HGH antibody. 
312 Von WERDER et al. 













FIG. 2. Dilution curve of a serum containing 5. 6 ng HGH/ml and 3200 ng HPr/ml (o) showing parallelism 
to the HGH Standard curve (•). Deviating dilution curves of eight serum samples from pregnant women 
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FIG. 3. HGH Standard curve (o 
patients (± SE). 
•o). The points ( •) result from serum dilutions of ten acromegalic 
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FIG. 4. Left: HGH response to insulin hypoglycaemia in eight subjects (• • ). Right: dilution 
curve of all 30-, 45- and 60-min samples •*) and the 90-min samples (•— — —•) compared 
with the Standard curve ( ) (± SE). 
c r o s s - r e a c t i v i t y w i t h H P L and no c r o s s - r e a c t i v i t y w i t h L H (3. 7 N I H - L H - S j / m g 
protein) and bovine p r o l a c t i n ( B P r ) . C r o s s - r e a c t i v i t y of endogenous H P L 
wi th the H G H antibody was d e m o n s t r a t e d by the devia t ion of the d i l u t i o n 
c u r v e s of eight s e r u m s a m p l e s f r o m pregnant women w i t h a mean H P L 
concentra t ion of 12.3 ± 2 .3 jug/ml ± SD ( F i g . 2). The s e r u m of a patient 
w i t h a p r o l a c t i n - p r o d u c i n g adenoma conta ining 5 .6 ng H G H / m l and high 
endogenous i m m u n o a s s a y a b l e human p r o l a c t i n (3200 ng/ml) showed no 
deviat ion f r o m the Standard c u r v e ( f ig . 2). The d i l u t i o n c u r v e s of 10 s e r u m 
s a m p l e s f r o m patients wi th ac t ive a c r o m e g a l y a lso d id not deviate f r o m the 
s lope of the Standard d i lu t ions ( F i g . 3). The H G H concentra t ion ranged f r o m 
14 n g / m l to 200 n g / m l . In three patients s a m p l e s w e r e a l s o taken f r o m the 
j u g u l a r v e i n where the H G H c o n c e n t r a t i o n was 1.1 to 2 .4 t i m e s h i g h e r than 
i n the c u b i t a l v e i n . These findings demonstrate i m m u n o i d e n t i t y between 
H G H f r o m a c r o m e g a l i c s ' s e r u m and H G H Standards. 
T h e H G H r e s p o n s e to i n s u l i n - i n d u c e d h y p o g l y c a e m i a of eight non-obese 
subjects w i t h n o r m a l p i t u i t a r y function i s depicted i n the lef t part of F i g . 4 . 
These i n s u l i n h y p o g l y c a e m i a tes ts w e r e used for o u r d i l u t i o n studies s ince 
they showed a r a t h e r h igh r i s e of H G H c o m p a r e d wi th that of 54 subjects 
who had a m e a n m a x i m a l H G H r i s e to 39. 9 ± 3. 0 n g / m l ± SE r a n g i n g f r o m 
16.5 to 92 .0 n g / m l . The s e r u m s a m p l e s of the eight subjects w e r e di luted 
and the r e s u l t i n g d i l u t i o n c u r v e s of the 30- 45- and 6 0 - m i n s a m p l e s were 
shown to be p a r a l l e l to the Standard c u r v e . Only the d i l u t i o n c u r v e s of the 
9 0 - m i n s a m p l e deviated s i g n i f i c a n t l y f r o m the Standard c u r v e and the other 
d i l u t i o n c u r v e s ( F i g . 4). 
D e x t r a n ge l f i l t r a t i o n of l a b e l l e d growth hormone r e v e a l e d three r a d i o -
act ive peaks ( F i g . 5). The f i r s t peak bound only p o o r l y to the ant ibody. A 
second peak eluted at K D 0 .45 and the t h i r d and l a r g e s t r a d i o a c t i v e peak 
eluted at K D 0. 8, r e p r e s e n t i n g the l a b e l l e d r e g u l ä r H G H . D e x t r a n gel 
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FIG. 5. Chromatography of 1 2 5 I - H G H on Sephadex G-75 (top). Three distinct peaks can be seen, the first 
eluting at K D 0.18 (peak I), the second eluting at K D 0.45 (peak II) and the third eluting at Kp 0. 8 (peak III) 
representing regulär HGH, used as tracer for radioimmunoassay. Pituitary HGH (middle) and acromegalic 
serum HGH (bottom) elutes in a similar pattern. The immunoreactivity in the area under peak I is small in 
relation to the radioactivity, but was found consistently. 
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FIG. 7. Discrepancy of measured and calcuiated concentration of HGH immunoreactivity of peak I and 
peak II. Peak III shows good agreement between measured and calcuiated results. Two different antibodies 
were used: goat anti-HGH (•) and guinea-pig anti-HGH (•). 
2mg HGH 2mg HGH 
t (min) t(min) 
FIG. 8. HGH levels in subjects with normal pituitary function (o o) and patients with HGH deficiency 
(• •) after infusion of 2 mg of pituitary HGH. 
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FIG. 9. Good agreement between measured and calcuiated HGH concentrations in the different dilutions of 
serum samples taken after infusion with 2 mg of pituitary HGH in subjects with and without endogenous HGH. 
f i l t r a t i o n of c l i n i c a l - g r a d e p i t u i t a r y growth h o r m o n e and endogenous H G H 
f r o m a patient w i t h a c r o m e g a l y and e x t r e m e l y e levated H G H l e v e l s 
(3100 ng/ml) a l s o showed t h r e e peaks ( F i g . 5). The homogenei ty of i m m u n o -
r e a c t i v e f r a c t i o n s obtained under peak II and peak III was c o n f i r m e d by 
r e c h r o m a t o g r a p h y ( F i g . 6). If the d i l u t i o n s of the f r a c t i o n s conta in ing peak 
I E w e r e a n a l y s e d for t h e i r H G H c o n c e n t r a t i o n the m e a s u r e d H G H concen-
t r a t i o n was found to be i d e n t i c a l w i t h the c a l c u i a t e d H G H content ( F i g . 7). 
The d i l u t i o n c u r v e of the i m m u n o r e a c t i v i t y of peak II showed a devia t ion 
f r o m the Standard d i l u t i o n c u r v e r e s u l t i n g i n d i s c r e p a n c y between m e a s u r e d 
and c a l c u i a t e d H G H concent ra t ions i n the di f ferent d i l u t i o n s . T h i s was even 
m o r e pronounced for the i m m u n o r e a c t i v i t y of peak I. The i m m u n o r e a c t i v i t y 
of the l a r g e r m o l e c u l a r weight f r a c t i o n s was d e m o n s t r a t e d to be dif ferent 
f r o m that of the H G H Standard w i t h two di f ferent ant ibodies ( F i g . 7). 
The i n f u s i o n of 2 m g of H G H into pat ients w i t h r e g u l ä r H G H s e c r e t i o n 
r e s u l t e d i n a H G H r i s e of 1 71. 6 ± 19.8 n g / m l . The H G H l e v e l i n patients 
wi th endogenous H G H d e f i c i e n c y r o s e a f ter i n f u s i o n to 192.4 ± 34.8 n g / m l 
( F i g . 8) . T h e d i f f e rence in h a l f - t i m e of the d i sappearance f r o m the s e r u m 
of the H G H i m m u n o r e a c t i v i t y between the two groups was not s i g n i f i c a n t : 
14 .9 ± 3 .9 m i n in subjects w i t h n o r m a l H G H s e c r e t i o n and 19.1 ± 6 m i n in 
patients without endogenous H G H s e c r e t i o n . The d i l u t i o n c u r v e s of the 
s e r u m s a m p l e s of both groups taken u n t i l 2 h o u r s af ter the s tar t of the 
i n f u s i o n w e r e p a r a l l e l to the d i l u t i o n of the in fused H G H Standard. T h e r e 
was t h e r e f o r e no d i f f e r e n c e between m e a s u r e d and c a l c u i a t e d H G H concen-
t r a t i o n i n the s e r u m d i l u t i o n s ( F i g . 9). 
D I S C U S S I O N 
S p e c i f i c i t y is e s s e n t i a l f o r r a d i o i m m u n o a s s a y of h o r m o n e s . It r e l i e s 
on an ant igenic determinant p a r t — i n the case of peptide h o r m o n e s a c e r t a i n 
CO 
CO 
I-HOH-Peafc 1 ^I-HOH-Ptfak H 125IZHGH-Peak_m 
HGH l n 9 ' m l ) HGH ( n 9 , m , ) HGH { n * ' m " 
FIG. 10. Standard curves of "big-big" (• •), "big" (o o) and "little" ( a £ ) HGH with 
different 1 2 5 I - H G H tracers. Only "big-big" HGH inhibits 1 2 5 I-HGH-peak I binding to the antibody. The 
inhibition curves of the different HGH fractions are superimposable only when 1 2 5 I-HGH-peak III, i .e . the 
purified labelled "little" HGH, is used. 
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amino acid sequence — which i s unique for the hormone to be measured. The 
structure of H G H has been revised r e c e n t l y [4] . A c c o r d i n g to L i et al . it 
is a Single-chain peptide with 190 amino acids, two disulphide bridges and 
a molecular weight of 21 500. B o v i n e and human prolactin ( B P r , H P r ) seem 
to be very similar to H G H [ 12 ] . It is therefore surprising that H G H anti-
bodies do not cross-react with B P r and H P r . The fact that there i s no 
cross-reactivity i s proven by the failure of B P r to inhibit 1 2 5 I - H G H binding 
to the antibody and by identity of the slope of the serum dilution curve 
prepared with H G H in the presence of a high concentration of H P r with the 
slope of the H G H Standard curve. If the H P r were to react with the H G H 
antibody the serum dilution would deviate from the Standard slope and the 
measurement of H G H would not be possible since one of the basic criteria 
for the validity of radioimmunoassays — identity of the dilution curves of 
Standard and unknown — i s not fulfilled. 
H P L i s a peptide hormone with 190 amino acids, two disulphide b r i d g e s 
and a molecular weight of 21 000 [ 13] . S ince 160 of the 190 amino-acid 
residues of H P L occupy positions that are i d e n t i c a l to those in H G H it i s not 
surprising that both hormones have similar ant igenic determinants. B e c a u s e 
of the resulting cross-reactivity H G H measurements during pregnancy will 
remain difficult. T h i s has been demonstrated before and is again pointed 
out by our results which show inhibition of 1 2 5 I - H G H binding to the H G H anti-
body by H P L Standards ( F i g . l ) and non-parallelism of the H G H Standard 
curves and the serum dilution curves for pregnant women. S ince the other 
pituitary hormones have no structural similarity to H G H , cross-reactivity 
of these hormones with the H G H antibody should not occur. The displacement 
of 1 2 5 I - H G H by the T S H Standard must be due to contamination of this 
preparation, as is demonstrated by the parallel TSH-inhibition curve ( F i g . l ) 
and the absence of interference from elevated endogenous T S H in the H G H 
immunoassay (unpublished data). A c c o r d i n g to these findings the only 
material in non-pregnant women that reacts with the H G H antibody should be 
H G H . U n l e s s the H G H i s a l t e r e d , dilution curves of serum containing H G H 
and Standards should be parallel. T h e immunoidentity of four different 
H G H preparations was documented in th i s manner. In contrast to Greenwood 
et al . [ 1 4 ] , who described one acromegalic patient with circulating H G H 
immunologically different from the Standard preparation, we found identical 
H G H immunoreactivity in all our patients ( F i g . 3). When subjects with 
normal H G H secretion were investigated we found that individuals with very 
pronounced H G H responses to insulin hypoglycaemia showed a change in 
immunoreactivity 90 min after insulin was given ( F i g . 4 ) . L a n d o n et a l . [23] 
also found a change in A C T H immunoreactivity after maximal Stimulation 
of its secretion. These findings could be explained by two different 
mechanisms: 
1. C a t a b o l i s m of the circulating antigenic peptide gives r i s e to fragments 
of the antigen which only have partial immunoreactivity. 
2. A f t e r maximal Stimulation the pituitary secretes precursor hormones 
which differ immunologically from the original hormone. 
H e t e r o g e n e i t y in molecular size of peptide hormones has been described 
[ 7-11 ] . H G H immunoreactivity has been shown to be present in various 
molecular fractions [5 , 6, 7, 2 4 ] . O u r r e s u l t s demonstrating H G H immuno-
reactivity eluting in a less retarded peak from the Sephadex column are in 
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good agreement wi th these of Görden et a l . [ 6J and G o o d m a n et a l . [ 7 j , 
who found the l e s s r e t a r d e d " b i g " H G H (peak II, F i g . 5) i n p i t u i t a r y H G H , in 
s e r u m of a c r o m e g a l i c s and in s e r u m of subjects wi th n o r m a l H G H s e c r e t i o n . 
They a l so found i m m u n o r e a c t i v i t y be ing e luted before " b i g " H G H i n some of 
t h e i r s a m p l e s . In our studies s igni f i cant amounts of i m m u n o r e a c t i v e 
m a t e r i a l w e r e a lways e luted just ahead of a l b u m i n (peak I, F i g . 5), w h i c h 
has a l so been demonst ra ted by B e r s o n and Y a l o w [ 24 ] . A c c o r d i n g to 
Goodman et a l . [7] " b i g " and regulär H G H have i d e n t i c a l i m m u n o r e a c t i v i t y 
[ 7] . B y us ing the r e c e p t o r a s s a y G o r d o n et a l . [6] showed i n p r e l i m i n a r y 
s tudies a l o w e r af f in i ty to the r e c e p t o r of " b i g " c o m p a r e d w i t h r e g u l ä r H G H . 
O u r studies demonstra te w i t h two di f ferent a n t i s e r a to H G H that " b i g " 
(peak II) and m o r e pronounced " b i g - b i g " (peak I) reac t d i f f e r e n t l y w i t h the 
H G H - a n t i b o d i e s , c o m p a r e d to r e g u l ä r H G H (peak III). S ince the d i f f e r e n c e 
i n i m m u n o r e a c t i v i t y between " b i g " and r e g u l ä r H G H i s not so obvious and 
w i l l d i f f e r depending on the antibody used, t h i s may e x p l a i n the d i s c r e p a n c y 
between our r e s u l t s and those of Goodman et a l . The i m m u n o r e a c t i v i t y of 
" b i g - b i g " H G H has not been inves t iga ted by these a u t h o r s . Of i n t e r e s t i s 
the f inding that s e r u m of a c r o m e g a l i c s contain l e s s " b i g " H G H than s e r u m 
of patients a f ter i n s u l i n h y p o g l y c a e m i a [ 6 ] , One could a s s u m e , t h e r e f o r e , 
that the change in H G H i m m u n o r e a c t i v i t y du r i n g i n s u l i n h y p o g l y c a e m i a i s 
due to the i n c r e a s e of " b i g " and, maybe , " b i g - b i g " H G H i n the s e r u m . 
" B i g " f o r m s of H G H a r e able to cause better i n h i b i t i o n of 1 2 5 I - H G H peak II 
than " l i t t l e " H G H w h i c h causes a change i n the s lope of the i n h i b i t i o n c u r v e 
( F i g . 10). The c o n v e r s i o n of in fused H G H into l a r g e r i m m u n o r e a c t i v e m o l e -
cu les i n the c i r c u l a t i o n i s i m p r o b a b l e s ince no i m m u n o l o g i c a l changes i n 
c i r c u l a t i n g H G H can be o b s e r v e d o v e r a p e r i o d of 2 h o u r s a f t e r i n f u s i o n 
( F i g . 9 ) . 
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D I S C U S S I O N 
R o s a l y n S. Y A L O W : Y o u r l a r g e r growth hormone (GH) components 
s e e m to be m u c h m o r e stable than the " b i g " G H of other w o r k e r s . A r e 
there any p a r t i c u l a r methods which help i n m a i n t a i n i n g the s t a b i l i t y of the 
" b i g " f o r m ? 
F r o h m a n and F r i e s e n c a r r i e d out independent b iosynthet i c s tudies to 
e s t a b l i s h the p r e c u r s o r nature of the two l a r g e r h o r m o n a l f o r m s , and a l so 
noted a u s u a l l y r a p i d appearance of l a b e l l e d amino ac ids i n the " l i t t l e " f o r m , 
again s u g g e s t i n g l a c k of s t a b i l i t y of the " b i g g e r " f o r m s , as c o m p a r e d to the 
" b i g g e r " f o r m s of other h o r m o n e s , s u c h as i n s u l i n or g a s t r i n . 
T h e q u e s t i o n of s t a b i l i t y i s i m p o r t a n t in c o n s i d e r i n g whether the " b i g g e r " 
f o r m s r e s u l t f r o m covalent bonding. 
K . v o n W E R D E R : We have, i n fact , seen v e r y l i t t l e c o n v e r s i o n of " b i g " 
into " l i t t l e " H G H , even af ter s torage of the " b i g " H G H p r e p a r a t i o n f o r four 
w e e k s . T h e s e r e s u l t s a r e , h o w e v e r , i n contras t to the f indings of Goodman 
et a l . 1 and Görden et a l . 2 . O u r methodology d i f f e r s f r o m t h e i r s i n that we 
use 0. 05 M phosphate buffer f o r e lu t ion , and per f o r m our g e l f i l t r a t i o n 
at 24°C. 
S ince G o o d m a n et a l . r e c e n t l y r e p o r t e d at Chicago that there i s a 
l a b i l e " b i g " H G H , w h i c h i s conver t ib le into " l i t t l e " H G H by 6 M u r e a , as 
w e l l as b y f r e e z i n g and thawing the " b i g " H G H p r e p a r a t i o n , and that there 
i s i n a d d i t i o n a stable f o r m of the " b i g " h o r m o n e w h i c h i s not so c o n v e r t e d , 
i t might be that we a r e dea l ing m a i n l y w i t h the l a t t e r . O u r s e r u m s a m p l e s 
w e r e f r o z e n and thawed at leas t once and so m o s t of the c o n v e r t i b l e " b i g " 
H G H may have been c o n v e r t e d . The " b i g " H G H r e m a i n i n g was there fore 
i n the s table f o r m . We b e l i e v e , as suggested by G o o d m a n , that we are 
d e a l i n g w i t h two f o r m s of " b i g " H G H , one of w h i c h i s not cova lent ly bound 
to another p r o t e i n , w h i l e the other i s . The l a t t e r i s the stable f o r m and, 
i n our o p i n i o n , a t r u e p r e c u r s o r h o r m o n e . 
1 See Ref. [7] of the paper. 
2 See Ref. [6] of the paper. 
